Back to Search
Start Over
MaxCyte Signs Strategic Platform License with Lyell Immunopharma
- Source :
- Plus Company Updates. July 7, 2023
- Publication Year :
- 2023
-
Abstract
- ROCKVILLE, Md: MaxCyte, Inc has issued the following news release: MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- Plus Company Updates
- Publication Type :
- News
- Accession number :
- edsgcl.757953880